证券代码：300239 证券简称：东宝生物 公告编号：2025-051 债券代码：123214 债券简称：东宝转债 包头东宝生物技术股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 包头东宝生物技术股份有限公司(以下简称"东宝生物"或"公司")于2025 年1月3日召开第九届董事会第八次会议、第九届监事会第七次会议，审议通过了 《关于回购公司股份方案的议案》，使用公司自有资金和/或自筹资金以集中竞 价交易方式或法律法规允许的方式回购公司已发行的人民币普通股(A股)股票， 回购的公司股份用于实施员工持股计划或股权激励。本次回购股份不低于人民币 5,000万元(含)，且不超过人民币10,000万元(含)，具体回购资金总额以回购期限 届满时或者回购股份实施完毕时实际回购股份使用的成交资金总额为准。本次回 购价格不超过人民币8.00元/股(含)，本次回购股份的实施期限自公司董事会审议 通过回购股份方案之日起12个月内。因公司实施2024年度权益分派，公司本次回 购价格上限由不超过人民币8.00元/股(含)调整为不超过人民币7.9 ...

证券代码：300239 证券简称：东宝生物 转债代码：123214 转债简称：东宝转债 包头东宝生物技术股份有限公司 向不特定对象发行可转换公司债券 受托管理事务报告（2024 年度） 发行人：包头东宝生物技术股份有限公司 （内蒙古自治区包头市稀土开发区黄河大街 46 号） 受托管理人：招商证券股份有限公司 （广东省深圳市福田区福田街道福华一路 111 号） 2025 年 6 月 重要声明 依据《可转换公司债券管理办法》（以下简称"《管理办法》"）、《包头 东宝生物技术股份有限公司向不特定对象发行可转换公司债券募集说明书》（以 下简称"《募集说明书》"）、《包头东宝生物技术股份有限公司（作为债券发 行人）与招商证券股份有限公司（作为债券受托管理人）关于包头东宝生物技术 股份有限公司可转换公司债券受托管理协议》（以下简称"《受托管理协议》" ） 等相关规定及约定，招商证券股份有限公司（以下简称"招商证券"、"受托管 理人"）作为本次债券的受托管理人编制本报告。招商证券编制本报告的内容及 信息均来源于公开信息、包头东宝生物技术股份有限公司（以下简称"公司"、 "发行人"、"东宝生物"）对外发布的《包头东宝生物技术 ...

Core Viewpoint - The article highlights the increasing environmental risks faced by listed companies in China, emphasizing the importance of transparency in environmental information and the potential impact on investors [10][11][16]. Group 1: Environmental Violations and Penalties - Five listed companies were recently identified for environmental violations, with a total of 41.99 million shareholders potentially affected by these risks [12]. - Chengxing Co., Ltd. was fined approximately 206,680 yuan for illegally occupying forest and grassland during soil dumping activities [12][13]. - Dongbao Biological's joint venture, Mengbao Biotechnology, was fined 300,000 yuan for discharging pollutants without a permit [14]. - Hanjiabao Coal Company was fined 210,000 yuan for operating a coal boiler without environmental approval [15]. Group 2: Regulatory Framework and Public Awareness - The article discusses the evolution of environmental information disclosure regulations in China, highlighting the legal rights of citizens and organizations to access environmental data [16]. - The increasing emphasis on ESG (Environmental, Social, and Governance) investment principles is noted, with investors becoming more aware of companies' sustainable development capabilities [16].

Core Viewpoint - The company maintains a stable credit rating outlook while facing challenges such as declining revenue and net profit due to changes in downstream industry policies and market fluctuations [3][5][6]. Company Overview - The company, Baotou Dongbao Biotechnology Co., Ltd., has acquired full ownership of Qingdao Yiqing Biotechnology Co., Ltd., enhancing its vertical integration in the gelatin and hollow capsule industries [3][5]. - The company specializes in the research, production, and sales of gelatin, collagen, hollow capsules, and related products, with a focus on expanding its market presence [5][20]. Financial Performance - For 2024, the company reported total assets of 25.92 billion, total liabilities of 6.26 billion, operating income of 1.88 billion, and net profit of 0.19 billion [3][4]. - The company's revenue and net profit have shown a year-on-year decline due to price reductions in gelatin products and inventory destocking by customers [5][16]. - The operating cash flow remains positive, indicating a stable cash position despite the revenue decline [24]. Industry Environment - The gelatin and collagen industries are experiencing increased regulatory scrutiny, leading to market consolidation and heightened competition among manufacturers [11][12]. - The hollow capsule market is closely tied to the pharmaceutical industry, with growing demand driven by increased health awareness and changing medication habits among consumers [14][15]. Production and Capacity - The company has a gelatin production capacity of 13,500 tons per year, with a utilization rate of 72.07% in 2024, reflecting a decrease from the previous year [16][17]. - The hollow capsule production capacity has increased to 360 billion capsules per year, with a production volume of 304.42 billion capsules in 2024 [21][22]. Risks and Challenges - The company faces risks related to the realization of returns from ongoing projects and the potential for underutilization of production capacity [6][23]. - High equity pledge rates among major shareholders pose a risk of forced liquidation, which could impact the company's financial stability [7][20].

2023 年包头东宝生物技术股份有 限公司向不特定对象发行可转换 公司债券 2025 年跟踪评级报告 中鹏信评【2025】跟踪第【87】号 01 信用评级报告声明 除因本次评级事项本评级机构与评级对象构成委托关系外，本评级机构及评级从业人员与评级对象不存 在任何足以影响评级行为独立、客观、公正的关联关系。 中证鹏元资信评估股份有限公司 本评级机构与评级从业人员已履行尽职调查义务，有充分理由保证所出具的评级报告遵循了真实、客观、 公正原则，但不对评级对象及其相关方提供或已正式对外公布信息的合法性、真实性、准确性和完整性 作任何保证。 本评级机构依据内部信用评级标准和工作程序对评级结果作出独立判断，不受任何组织或个人的影响。 本评级报告观点仅为本评级机构对评级对象信用状况的个体意见，不作为购买、出售、持有任何证券的 建议。本评级机构不对任何机构或个人因使用本评级报告及评级结果而导致的任何损失负责。 本次评级结果自本评级报告所注明日期起生效，有效期为被评证券的存续期。同时，本评级机构已对受 评对象的跟踪评级事项做出了明确安排，并有权在被评证券存续期间变更信用评级。本评级机构提醒报 告使用者应及时登陆本公司网站关注被 ...

| 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2025-050 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 包头东宝生物技术股份有限公司 关于"东宝转债"恢复转股的提示性公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 债券代码：123214 特别提示： 根据《包头东宝生物技术股份有限公司向不特定对象发行可转换公司债券募集 说明书》相关规定，"东宝转债"将于本次权益分派股权登记日后的第一个交易日， 即2025年6月17日（除权除息日）起恢复转股。 敬请公司可转换公司债券持有人注意。 特此公告。 包头东宝生物技术股份有限公司 债券简称：东宝转债 转股起止时间：2024 年 2 月 5 日至 2029 年 7 月 30 日 暂停转股时间：2025 年 6 月 9 日起至 2025 年 6 月 16 日 恢复转股时间：2025 年 6 月 17 日 包头东宝生物技术股份有限公司（以下简称"公司"）因实施 2024 年度权益分 派，根据《包头东宝生物技术股份有限公司向不特定对象发行可转换 ...

Core Points - Dongbao Biological (300239) closed at 5.6 yuan on June 13, 2025, a 0.36% increase from the previous week's 5.58 yuan [1] - The company has a total market capitalization of 3.324 billion yuan, ranking 45th out of 50 in the bioproducts sector and 3972nd out of 5150 in the A-share market [1] Company Announcements - Dongbao Biological announced a cash dividend of 0.25 yuan per 10 shares (including tax) for the 2024 fiscal year, with the record date on June 16, 2025, and the ex-dividend date on June 17, 2025 [1][4] - The company will not issue new shares or use capital reserves for this dividend distribution, and the remaining undistributed profits will be carried forward to future distributions [1] - The adjusted cash dividend per 10 shares after the distribution will be approximately 0.245546 yuan (including tax) [1] Convertible Bond Adjustments - The conversion price for Dongbao Convertible Bonds (123214) will be adjusted from 6.65 yuan to 6.63 yuan per share, effective June 17, 2025 [2][4] - The company issued 455 million yuan worth of convertible bonds, with a total of 4.55 million bonds available for conversion [2] Share Buyback Adjustments - Following the 2024 dividend distribution, the maximum buyback price will be adjusted from 8.00 yuan to 7.98 yuan per share, with the expected buyback quantity adjusted to between 6,265,700 and 12,531,300 shares [3][4] - The buyback plan was approved on January 3, 2025, with a duration of 12 months [3]

Core Viewpoint - The company has announced a profit distribution plan for the fiscal year 2024, which includes a cash dividend of RMB 0.25 per 10 shares (tax included) to all shareholders, excluding shares held in the repurchase account [1][2][4]. Summary by Sections Profit Distribution Plan - The profit distribution plan was approved at the shareholders' meeting on May 15, 2025, with a cash dividend of RMB 0.25 per 10 shares (tax included) to all shareholders, without issuing bonus shares or capital reserve conversion [2][4]. - The total number of shares eligible for the dividend is calculated by deducting the repurchased shares from the total share capital as of the record date [3][4]. Dividend Calculation - The total cash dividend amount is adjusted based on the number of shares held after accounting for repurchased shares, resulting in a total cash dividend of RMB 14,575,863.32 (tax included) [3][4]. - The cash dividend per share is calculated as the total cash dividend divided by the adjusted total share capital, leading to a reference price adjustment for the ex-dividend date [6]. Key Dates - The record date for the dividend distribution is set for June 16, 2025, with the ex-dividend date on June 17, 2025 [5]. - Shareholders registered by the record date will receive the cash dividend directly into their accounts through their custodial securities companies [5]. Adjustments and Regulations - The company’s repurchased shares will not participate in this dividend distribution, and the conversion price of the company's convertible bonds will be adjusted accordingly [6].

Group 1 - The company has issued convertible bonds amounting to 455 million yuan, with a face value of 100 yuan per bond, totaling 4,550,000 bonds [1] - The initial conversion price for the convertible bonds was set at 6.67 yuan per share, which has been adjusted to 6.65 yuan per share effective from May 31, 2024 [2] - The adjusted conversion price after the latest cash dividend distribution is 6.63 yuan per share, effective from June 17, 2025 [4] Group 2 - The company will adjust the conversion price based on various corporate actions such as stock dividends, capital increases, and cash dividends, following specific formulas [1][2] - The company will disclose any adjustments to the conversion price through official announcements on the Shenzhen Stock Exchange or other designated media [2] - The company has a profit distribution plan for 2024, which does not include stock dividends or capital increases, and will carry forward undistributed profits to future distributions [3]

证券代码：300239 证券简称：东宝生物 公告编号：2025-049 债券代码：123214 债券简称：东宝转债 包头东宝生物技术股份有限公司 关于 2024 年度权益分派实施后调整 回购股份价格上限和数量的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 包头东宝生物技术股份有限公司(以下简称"公司")于 2025 年 1 月 3 日召 开第九届董事会第八次会议、第九届监事会第七次会议，审议通过了《关于回购 公司股份方案的议案》。根据相关法律法规及《公司章程》规定，本次回购股份 方案无需提交公司股东大会审议。使用公司自有资金和/或自筹资金以集中竞价 交易方式或法律法规允许的方式回购部分公司已发行的人民币普通股(A 股)股票， 并在未来适宜时机将回购股份用于实施员工持股计划或股权激励。本次回购价格 不超过人民币 8.00 元/股(含)，本次回购股份的实施期限为公司董事会审议通过 回购股份方案之日起 12 个月内。按照回购股份价格上限人民币 8.00 元/股，回 购金额下限人民币 5,000 万元-上限人民币 10,000 万元(含)测算，预计回购股份 数 ...